Essential Factors To Consider In Fill-Finish Manufacturing

Fill and finish is the ultimate manufacturing step in creating an aseptic drug product, after which the product is passed to the patient. When a producer is debating whether to adopt single-use technology, product quality and the potential for contamination are of particular concern. There is increased sensitivity to sterility issues and the introduction of particles because the fill happens after the final filtration stage. Product and material interactions occur with all throwaway applications. Extractable and leachable are also concerns.

With a 9.5% compound annual growth rate (CAGR) anticipated for the following eight years, the international biopharmaceuticals market is expected to expand quickly. That amounts to predicted growth of more than $500 billion. Therefore, it is not surprising that biopharmaceutical manufacturers are making significant investments in new facilities, technology, and pipelines for manufacturing drug products.

A growing number of bio manufacturers are using new aseptic fill finish technologies, including a blow-fill-seal system and single-use equipment, even though such innovative technologies are progressively being utilized. The fundamental requirements for fill-finish operations are still the same: that is, preventing contamination of the equipment and formulations and packaging the product in a way that maintains the biochemical conditions that will be most favorable for each biopharmaceutical product.

Here are some comprehensive overviews of core considerations in fill finish processes.

1. Create a Facility that Protects Aseptic Conditions

The facility layout where the operation will take place is the first factor to be considered when developing a fill-finish process. A cleanroom is necessary for an aseptic fill-finish system, and maintaining this aseptic environment needs much more than simply sterilizing equipment.

For instance, the air in a cleanroom needs to be filtered using a high-efficiency particulate air (HEPA) system. It's vital to keep an eye on this airflow since even trace levels of pollutants can compromise the sterility of an entire manufacturing system.

2. Sterilization Methods Need to Be Fit for Formulation and Equipment

Equipment and containers must be sterilized before they can be used in a cleanroom. Systems used to sterilize equipment must be carefully chosen because each method will affect various formulations, packaging materials, and different sorts of contaminants that could be present on equipment and items used in a fill finish process differently.

3. Manufacturing must Be Aseptically Conducted

Before being bottled, many biologics are lyophilized. Adding a sterile fill-finish phase increases the dangers and difficulties of lyophilization, necessitating the construction of a packing pipeline with a short transfer time between a lyophilizer and vial or bottle filling.

4. Automatic Fill finish

While adding automation technology to a fill-finish process has many apparent advantages, it also limits nimble production. Automation eliminates human error and increases a manufacturer's capacity to meet output limits on short notice by making the fill-finish process consistent and endlessly repeatable.

Fill Finish Your Drugs at AbbVie

Most biomanufacturing operations and fill finish activities are outsourced, and more respondents say they outsource fill/finish operations annually. Even though there is plenty of internal capability, outsourcing fill finish activities are undoubtedly deep-rooted.

At AbbVie, we offer two convenient aseptic fill-finish options for parenteral drug products: prefilled syringes and vials. Get development & manufacturing support for your product formulations. For your pharmaceutical fill finish needs, contact us today.